Free Trial
NASDAQ:TNXP

Tonix Pharmaceuticals Q1 2025 Earnings Report

Tonix Pharmaceuticals logo
$47.70 +3.06 (+6.85%)
Closing price 04:00 PM Eastern
Extended Trading
$46.95 -0.75 (-1.58%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tonix Pharmaceuticals EPS Results

Actual EPS
-$2.84
Consensus EPS
-$3.23
Beat/Miss
Beat by +$0.39
One Year Ago EPS
N/A

Tonix Pharmaceuticals Revenue Results

Actual Revenue
$2.43 million
Expected Revenue
$2.55 million
Beat/Miss
Missed by -$121.00 thousand
YoY Revenue Growth
N/A

Tonix Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Tonix Pharmaceuticals' Q2 2025 earnings is scheduled for Friday, August 15, 2025, with a conference call scheduled on Monday, August 18, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tonix Pharmaceuticals Earnings Headlines

Zacks Small Cap Has Bullish Forecast for TNXP Q2 Earnings
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Tonix Pharma Plans Sales Force for TNX-102 SL
See More Tonix Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ:TNXP), a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

View Tonix Pharmaceuticals Profile

More Earnings Resources from MarketBeat